Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Several studies in the early 1990s demonstrated that cyclophosphamide (Cy) combined with oral busulfan was inferior to total body irradiation (TBI) for outcomes of myeloablative transplantation. However, since the development of IV busulfan preparations, the optimal preparative regimen has been controversial. Two manuscripts published in this week's issue of Blood compare the outcomes of hematopoietic cell transplant following preparation with cyclophosphamide plus total body irradiation (Cy-TBI) versus IV busulfan (Bu-Cy) and confirm superior results with Bu-Cy, including improved leukemia-free survival and reduced non-relapse mortality, suggesting that this regimen should be the standard of care.
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI, Edward A. Copelan, Betty K. Hamilton, Belinda Avalos, Kwang Woo Ahn, Brian J. Bolwell, Xiaochun Zhu, Mahmoud Aljurf, Koen van Besien, Christopher Bredeson, Jean-Yves Cahn, Luciano J. Costa, Marcos de Lima, Robert Peter Gale, Gregory A. Hale, Joerg Halter, Mehdi Hamadani, Yoshihiro Inamoto, Rammurti T. Kamble, Mark R. Litzow, Alison W. Loren, David I. Marks, Eduardo Olavarria, Vivek Roy, Mitchell Sabloff, Bipin N. Savani, Matthew Seftel, Harry C. Schouten, Celalettin Ustun, Edmund K. Waller, Daniel J. Weisdorf, Baldeep Wirk, Mary M. Horowitz, Mukta Arora, Jeff Szer, Jorge Cortes, Matt E. Kalaycio, Richard T. Maziarz, and Wael Saber, Blood - doi: 10.1182/blood-2013-07-514448
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Lymphoma / Leukemia / Myeloma category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Blood. "Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared to TBI." Medical News Today. MediLexicon, Intl., 9 Dec. 2013. Web.
24 Apr. 2014. <http://www.medicalnewstoday.com/releases/269851>
Blood. (2013, December 9). "Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared to TBI." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/269851.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT is the registered trade mark of MediLexicon International Limited.